Brought to you by 
Kiadis Pharma N.V.
http://www.kiadis.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kiadis Pharma N.V.
Re-Focused Kiadis Preps Trials With Natural Killer Cells
Kiadis Pharma’s CEO says its processed natural kill cell therapies can improve hematopoietic stem cell transplants and also treat resurgent leukemia.
Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
Roche’s Polivy Among Seven New Drugs On Track For EU-Wide Approval
Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.
Jumping Before They Were Pushed – Kiadis And Aradigm Withdraw EU Filings
Notice of the withdrawal of pan-EU marketing authorizations applications by Kiadis Pharma and Aradigm are noted in the agenda of the latest meeting of the European Medicines Agency's key scientific committee, the CHMP.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Celmed BioSciences, Inc.
- Kiadis Pharma B.V.